Individuals with EGFR+ NSCLC whose illness unfold exterior the mind after therapy with Tagrisso lived longer once they saved taking Tagrisso together with chemo: © inventory.adobe.com
Individuals with EGFR-positive non–small cell lung most cancers (NSCLC) whose illness unfold exterior the mind after therapy with Tagrisso lived longer once they saved taking Tagrisso together with chemotherapy, in line with a section 3 research shared on the 2025 World Convention on Lung Most cancers.
The info, which had been shared in a press briefing, indicated that the mix of Tagrisso and chemotherapy (49 sufferers) was linked with improved progression-free survival versus placebo plus chemotherapy (49 sufferers). The median progression-free survival within the respective arms was 8.4 months and 4.4 months. The info had been at 76% maturity and the median follow-up within the Tagrisso and placebo arms was 5.4 months and 5.5 months, respectively.
In evaluable sufferers with out baseline central nervous system metastases, the central nervous system progression-free survival with Tagrisso plus chemotherapy (38 sufferers) was longer, at 15.9 months, versus 8.6 months with placebo plus chemotherapy (37 sufferers). These information had been at 43% maturity, and the median follow-up was 5.5 months and 5.6 months within the respective arms. Furthermore, the Tagrisso mixture was additionally linked with improved non–central nervous system progression-free survival versus chemotherapy alone. The median non–central nervous system progression-free survival within the respective arms was 8.4 months and 5.2 months. Knowledge maturity was 73%, and the median follow-up was 3.6 months in each arms.
Furthermore, with information at 55% maturity, the median total survival was longer with Tagrisso plus chemotherapy versus placebo plus chemotherapy, at 15.9 months and 9.8 months, respectively. The median follow-up within the respective arms was 12 months and 11.1 months.
“These outcomes point out that resistance to first-line Tagrisso could also be heterogeneous, and a few tumor cells stay delicate to continued remedy,” Giulia Pasello, MD, PhD, of the Veneto Institute of Oncology IOV-IRCCS and the College of Padova in Padova, Italy, mentioned in a information launch. “This trial helps Tagrisso as a spine therapy technique on this setting.”
Within the Realm of EGFR-Mutated Non–Small Cell Lung Most cancers, What Did the Section 3 Research Look at?
The worldwide, randomized, double-blind, section 3 research enrolled sufferers with domestically superior or metastatic EGFR-mutated non–small cell lung most cancers with or with out central nervous system metastases. These sufferers had been no less than 18 years of age, skilled non–central nervous system development on first-line Tagrisso, and had a World Well being Group efficiency rating of 0 or 1; their EGFR mutations had been exon 19 deletion or L858R.
Research contributors (98 sufferers) had been randomized 1:1 to obtain placebo or 80 mg of Tagrisso as soon as each day plus 75 mg/m2 of cisplatin or space underneath the curve 5 of carboplatin plus 500 mg/m2 of pemetrexed given each 3 weeks for 4 cycles adopted by placebo or 80 mg of Tagrisso as soon as each day plus 500 mg/m2 of pemetrexed each 3 weeks. Remedy continued till progressive illness or different discontinuation standards had been met. Sufferers had been stratified by the presence of central nervous system metastases (sure versus no).
Imaging assessments of the chest and stomach and the mind had been carried out at baseline and each 6 weeks for the primary 13 cycles; they had been carried out each 12 weeks thereafter. The first finish level of the research was investigator-assessed progression-free survival, and key secondary finish factors comprised central nervous system progression-free survival in line with baseline central nervous system metastases standing, non–central nervous system progression-free survival, and total survival.
A complete of 98 sufferers had been randomized, and 96 sufferers had been dosed; 48 sufferers had been randomized to the Tagrisso arm and 48 had been randomized to the placebo arm; 15% and eight% of sufferers had been nonetheless receiving Tagrisso or placebo on the time of knowledge cutoff, which was October 28, 2024; 13% and eight% of sufferers within the respective arms had been nonetheless receiving pemetrexed.
Throughout the Tagrisso and placebo arms, the median affected person age was 62 years. Most sufferers had been feminine (61%; 80%), by no means people who smoke (65%; 67%), and White (80%; 78%), and about half had an ECOG efficiency standing of 1 (53%; 51%). Most sufferers had stage 4 illness by American Joint Committee on Most cancers standards on the time of research entry (100%; 98%). Central nervous system metastases had been current in 22% of these within the Tagrisso arm versus 24% of these within the placebo arm. The extra widespread EGFR mutation sort was exon 19 deletions (65%; 55%). The median time on first-line Tagrisso within the respective arms was 21.3 months and 19.6 months.
What Else Is Identified In regards to the Efficacy of Tagrisso Plus Chemotherapy on this Setting?
The 6-month progression-free survival price with Tagrisso plus chemotherapy was 64% versus 32% with placebo plus chemotherapy. The 6-month central nervous system progression-free survival charges had been 87% and 63% within the respective arms, and the 6-month non–central nervous system progression-free survival charges had been 65% and 35%, respectively. The 6-month total survival charges had been 67% and 47%.
The non–central nervous system goal response price within the Tagrisso arm (49 sufferers) was 35% versus 29% within the placebo arm (49 sufferers). The median non–central nervous system period of response was 8.2 months with Tagrisso versus 4.2 months with out.
New lesions had been reported in 37% of these within the Tagrisso arm versus 51% of these on the placebo arm, with fewer sufferers within the Tagrisso arm experiencing new mind lesions (10% versus 27%).
What’s the Aspect Impact Profile of Tagrisso Plus Chemotherapy?
Security information for the Tagrisso mixture aligned with what has beforehand been reported for every drug. Any-grade negative effects occurred in 98% of these within the Tagrisso and placebo arms; 63% and 46% of them had been grade 3 or larger. Critical negative effects had been skilled by 38% and 31% of sufferers within the respective arms, and negative effects proved deadly for 1 affected person in every arm. Unwanted effects led to discontinuation of Tagrisso or placebo, pemetrexed, or platinum for 13%, 19%, and 13% of sufferers within the Tagrisso arm; these respective charges had been 2%, 2%, and 0% within the placebo arm.
The commonest grade 3 negative effects within the Tagrisso and placebo arms had been anemia (13%; 13%), neutropenia (13%; 2%), decreased white blood cell depend (10%; 4%), decreased neutrophil depend (8%; 6%), decreased platelet depend (6%; 2%), elevated aspartate aminotransferase ranges (4%; 0%), nausea (2%; 0%), elevated alanine aminotransferase ranges (2%; 2%), and decreased urge for food (2%; 0%). The commonest grade 4 occasions within the Tagrisso arm had been neutropenia, elevated alanine aminotransferase ranges, decreased neutrophil depend, and decreased white blood cell depend (2% every). Within the placebo arm, these had been decreased platelet depend (4%) and neutropenia (2%).
References
- Pasello G, Zhao J, Tufman A, et al. COMPEL: Osimertinib + platinum-based chemotherapy in sufferers with EGFRm superior NSCLC and development on 1L osimertinib. Introduced at: 2025 Worldwide Affiliation for the Research of Lung Most cancers 2025 World Convention on Lung Most cancers; September 6-9, 2025; Barcelona, Spain. Summary 1174.
- COMPEL research exhibits persevering with osimertinib therapy by development with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC. Information launch. Worldwide Affiliation for the Research of Lung Most cancers 2025 World Convention on Lung Most cancers. September 6, 2025. Accessed September 6, 2025. https://wclc.iaslc.org/
- A research to judge chemotherapy plus osimertinib towards chemotherapy plus placebo in sufferers with non-small cell lung most cancers (NSCLC) (COMPEL). ClinicalTrials.gov. Up to date July 10, 2025. Accessed September 6, 2025. https://clinicaltrials.gov/research/NCT04765059
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
